中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 7
Jul.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(7): 1456-1460

The roles of eosinophils in different liver diseases

DOI: 10.12449/JCH250735
  • 1.

    Department of Gastroenterology，The 940 Hospital of Joint Logistic Support Force of PLA，Lanzhou 730050，China

  • 2.

    Department of Gastroenterology，General Hospital of Ningxia Medical University，Yinchuan 750001，China

Research funding:

Gansu Province Health Care Industry Research Program (GSWSKY2023-34);

Special Project for Graduate Supervisors of the 940th Hospital of the Joint Logistics Support Force of Chinese PLA (2023YXKY020)

More Information
  • Corresponding author: ZHANG Jiucong， zhangjiucong@163.com （ORCID： 0000-0003-4006-3033）
  • Received Date: 2024-11-21
  • Accepted Date: 2025-04-09
  • Published Date: 2025-07-25
    Abstract
  • Liver diseases have a high prevalence rate worldwide with relatively poor long-term clinical outcomes and have become one of the leading causes of disease burden and death around the world， which poses significant challenges to public health. Eosinophils （Eos） are a class of highly conserved multifunctional immune cells that play critical effector roles in allergic diseases. In recent years， an increasing amount of evidence has shown that Eos plays an important role in the pathogenesis of liver diseases， exerting a protective or harmful effect in different liver diseases， which has become a research hotspot in this field. This article elaborates on the role and potential mechanism of action of Eos in liver diseases， in order to provide a new perspective for in-depth research on the pathogenesis of liver diseases and lay the foundation for developing therapeutic strategies targeting Eos.

     

    • FullText(HTML)
  • loading
    • References(39)
  • [1]
    GRIFFIN C, AGBIM U, RAMANI A, et al. Underestimation of cirrhosis-related mortality in the medicare eligible population, 1999-2018[J]. Clin Gastroenterol Hepatol, 2023, 21( 1): 223- 225. e 3. DOI: 10.1016/j.cgh.2021.10.036.
    [2]
    DEVARBHAVI H, ASRANI SK, ARAB JP, et al. Global burden of liver disease: 2023 update[J]. J Hepatol, 2023, 79( 2): 516- 537. DOI: 10.1016/j.jhep.2023.03.017.
    [3]
    WECHSLER ME, MUNITZ A, ACKERMAN SJ, et al. Eosinophils in health and disease: A state-of-the-art review[J]. Mayo Clin Proc, 2021, 96( 10): 2694- 2707. DOI: 10.1016/j.mayocp.2021.04.025.
    [4]
    XIE LX, ZHANG HJ, XU L. The role of eosinophils in liver disease[J]. Cell Mol Gastroenterol Hepatol, 2025, 19( 2): 101413. DOI: 10.1016/j.jcmgh.2024.101413.
    [5]
    QIAN YH, ZHAO J, WU HL, et al. Innate immune regulation in inflammation resolution and liver regeneration in drug-induced liver injury[J]. Arch Toxicol, 2025, 99( 1): 115- 126. DOI: 10.1007/s00204-024-03886-0.
    [6]
    NI HM, LOPEZ-PASCUAL A. Eosinophils: A novel therapeutic target to promote liver regeneration in acute liver injury?[J]. Gut, 2024, 73( 9): 1409- 1411. DOI: 10.1136/gutjnl-2024-332692.
    [7]
    DOROSZ A, GROSICKI M, DYBAS J, et al. Eosinophils and neutrophils-molecular differences revealed by spontaneous Raman, CARS and fluorescence microscopy[J]. Cells, 2020, 9( 9): 2041. DOI: 10.3390/cells9092041.
    [8]
    AOKI A, HIRAHARA K, KIUCHI M, et al. Eosinophils: Cells known for over 140 years with broad and new functions[J]. Allergol Int, 2021, 70( 1): 3- 8. DOI: 10.1016/j.alit.2020.09.002.
    [9]
    KLION AD, ACKERMAN SJ, BOCHNER BS. Contributions of eosinophils to human health and disease[J]. Annu Rev Pathol, 2020, 15: 179- 209. DOI: 10.1146/annurev-pathmechdis-012419-032756.
    [10]
    RODRIGO-MUÑOZ JM, GIL-MARTÍNEZ M, SASTRE B, et al. Emerging evidence for pleiotropism of eosinophils[J]. Int J Mol Sci, 2021, 22( 13): 7075. DOI: 10.3390/ijms22137075.
    [11]
    GRISARU-TAL S, ITAN M, KLION AD, et al. A new dawn for eosinophils in the tumour microenvironment[J]. Nat Rev Cancer, 2020, 20( 10): 594- 607. DOI: 10.1038/s41568-020-0283-9.
    [12]
    VALENT P, DEGENFELD-SCHONBURG L, SADOVNIK I, et al. Eosinophils and eosinophil-associated disorders: Immunological, clinical, and molecular complexity[J]. Semin Immunopathol, 2021, 43( 3): 423- 438. DOI: 10.1007/s00281-021-00863-y.
    [13]
    JACOBSEN EA, JACKSON DJ, HEFFLER E, et al. Eosinophil knockout humans: Uncovering the role of eosinophils through eosinophil-directed biological therapies[J]. Annu Rev Immunol, 2021, 39: 719- 757. DOI: 10.1146/annurev-immunol-093019-125918.
    [14]
    SIDDIQUI S, BACHERT C, BJERMER L, et al. Eosinophils and tissue remodeling: Relevance to airway disease[J]. J Allergy Clin Immunol, 2023, 152( 4): 841- 857. DOI: 10.1016/j.jaci.2023.06.005.
    [15]
    COAKLEY G, WANG H, HARRIS NL. Intestinal eosinophils: Multifaceted roles in tissue homeostasis and disease[J]. Semin Immunopathol, 2021, 43( 3): 307- 317. DOI: 10.1007/s00281-021-00851-2.
    [16]
    XU JY, XIONG YY, TANG RJ, et al. Interleukin-5-induced eosinophil population improves cardiac function after myocardial infarction[J]. Cardiovasc Res, 2022, 118( 9): 2165- 2178. DOI: 10.1093/cvr/cvab237.
    [17]
    LIU J, YANG CZ, LIU TX, et al. Eosinophils improve cardiac function after myocardial infarction[J]. Nat Commun, 2020, 11( 1): 6396. DOI: 10.1038/s41467-020-19297-5.
    [18]
    LOPEZ-PEREZ D, PRADOS-LOPEZ B, GALVEZ J, et al. Eosinophils in colorectal cancer: Emerging insights into anti-tumoral mechanisms and clinical implications[J]. Int J Mol Sci, 2024, 25( 11): 6098. DOI: 10.3390/ijms25116098.
    [19]
    SHAH K, IGNACIO A, MCCOY KD, et al. The emerging roles of eosinophils in mucosal homeostasis[J]. Mucosal Immunol, 2020, 13( 4): 574- 583. DOI: 10.1038/s41385-020-0281-y.
    [20]
    PROCTOR WR, CHAKRABORTY M, CHEA LS, et al. Eosinophils mediate the pathogenesis of halothane-induced liver injury in mice[J]. Hepatology, 2013, 57( 5): 2026- 2036. DOI: 10.1002/hep.26196.
    [21]
    XU L, YANG Y, WEN YK, et al. Hepatic recruitment of eosinophils and their protective function during acute liver injury[J]. J Hepatol, 2022, 77( 2): 344- 352. DOI: 10.1016/j.jhep.2022.02.024.
    [22]
    XU L, YANG Y, JIANG JL, et al. Eosinophils protect against acetaminophen-induced liver injury through cyclooxygenase-mediated IL-4/IL-13 production[J]. Hepatology, 2023, 77( 2): 456- 465. DOI: 10.1002/hep.32609.
    [23]
    YANG Y, XU L, ATKINS C, et al. Novel IL-4/HB-EGF-dependent crosstalk between eosinophils and macrophages controls liver regeneration after ischaemia and reperfusion injury[J]. Gut, 2024, 73( 9): 1543- 1553. DOI: 10.1136/gutjnl-2024-332033.
    [24]
    WANG YC, YANG Y, WANG M, et al. Eosinophils attenuate hepatic ischemia-reperfusion injury in mice through ST2-dependent IL-13 production[J]. Sci Transl Med, 2021, 13( 579): eabb6576. DOI: 10.1126/scitranslmed.abb6576.
    [25]
    CAO Q, WANG RF, NIU ZG, et al. Type 2 innate lymphoid cells are protective against hepatic ischaemia/reperfusion injury[J]. JHEP Rep, 2023, 5( 10): 100837. DOI: 10.1016/j.jhepr.2023.100837.
    [26]
    LI BF, SUN R, WEI HM, et al. Interleukin-15 prevents concanavalin A-induced liver injury in mice via NKT cell-dependent mechanism[J]. Hepatology, 2006, 43( 6): 1211- 1219. DOI: 10.1002/hep.21174.
    [27]
    KREMER M, PERRY AW, MILTON RJ, et al. Pivotal role of Smad3 in a mouse model of T cell-mediated hepatitis[J]. Hepatology, 2008, 47( 1): 113- 126. DOI: 10.1002/hep.21956.
    [28]
    TARANTINO G, CABIBI D, CAMMÀ C, et al. Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C[J]. J Viral Hepat, 2008, 15( 7): 523- 530. DOI: 10.1111/j.1365-2893.2008.00976.x.
    [29]
    KATAOKA S, KONISHI Y, NISHIO Y, et al. Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma[J]. DNA Cell Biol, 2004, 23( 9): 549- 560. DOI: 10.1089/dna.2004.23.549.
    [30]
    Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug⁃Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese guideline for diagnosis and management of drug⁃induced liver injury(2023 Version)[J]. Chin J Gastroenterol, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176.

    中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 胃肠病学, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176.
    [31]
    LI ZL, CHEN LY, CHU HK, et al. Estrogen alleviates hepatocyte necroptosis depending on GPER in hepatic ischemia reperfusion injury[J]. J Physiol Biochem, 2022, 78( 1): 125- 137. DOI: 10.1007/s13105-021-00846-5.
    [32]
    FELD JJ, HEATHCOTE EJ. Epidemiology of autoimmune liver disease[J]. J Gastroenterol Hepatol, 2003, 18( 10): 1118- 1128. DOI: 10.1046/j.1440-1746.2003.03165.x.
    [33]
    LOUIS H, LE MOINE A, FLAMAND V, et al. Critical role of interleukin 5 and eosinophils in concanavalin A-induced hepatitis in mice[J]. Gastroenterology, 2002, 122( 7): 2001- 2010. DOI: 10.1053/gast.2002.33620.
    [34]
    MARTINELLO M, SOLOMON SS, TERRAULT NA, et al. Hepatitis C[J]. Lancet, 2023, 402( 10407): 1085- 1096. DOI: 10.1016/s0140-6736(23)01320-x.
    [35]
    LI F, LI B, ZHU QY. Research progress on the epidemiological characteristics and diagnosis of hepatitis C in China[J]. Int J Virol, 2023, 30( 6): 509- 511. DOI: 10.3760/cma.j.issn.1673-4092.2023.06.014.

    黎锋, 李博, 朱秋映. 中国丙肝流行特征与诊断研究进展[J]. 国际病毒学杂志, 2023, 30( 6): 509- 511. DOI: 10.3760/cma.j.issn.1673-4092.2023.06.014.
    [36]
    BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74( 3): 229- 263. DOI: 10.3322/caac.21834.
    [37]
    XIA CF, DONG XS, LI H, et al. Cancer statistics in China and United States, 2022: Profiles, trends, and determinants[J]. Chin Med J(Engl), 2022, 135( 5): 584- 590. DOI: 10.1097/CM9.0000000000002108.
    [38]
    WANG QH, ZHANG ZX, ZHOU H, et al. Eosinophil-associated genes are potential biomarkers for hepatocellular carcinoma prognosis[J]. J Cancer, 2024, 15( 17): 5605- 5621. DOI: 10.7150/jca.95138.
    [39]
    TOSHIDA K, ITOH S, YOSHIYA S, et al. Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2024, 39( 3): 576- 586. DOI: 10.1111/jgh.16441.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (380) PDF downloads(39) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return